In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

MicroRNAs - a novel target in cardiovascular prevention

  • Role in progression of atherosclerosis, presented by C Weber (Muenchen, DE) - Slides
  • Role in progenitor cell-mediated vascular and cardiac repair, presented by U Landmesser (Zurich, CH) - Slides
  • Targets in post-myocardial infarction, presented by G Condorelli (Milan, IT) - Slides
  • Developments of anti-miRs and miRmimics as novel therapeutics, presented by E Van Rooij (Boulder, US)
Basic Sciences, Pharmacology, Genomics and Cardiovascular Pathology

MicroRNAs (miRNAs) are small non-coding regulatory molecules that modify gene expression at the posttranscriptional level.

Role in progression of atherosclerosis

Christian Weber (Munich, DE) introduced the concept that endothelial miR-126 is a master regulator of atherosclerosis. Uptake of endothelial apoptotic bodies induced CXCL12 expression in endothelial cells, an important chemokine, which is inversely related to coronary artery disease in genome-wide association studies. Subsequent experiments showed that functional miR-126 was enriched in endothelial apoptotic bodies and had protective paracrine effects in apolipoprotein E-deficient mice, an animal model of atherosclerosis.

Role in progenitor cell-mediated vascular and cardiac repair

Ulf Landmesser (Zurich, CH) spoke about the role of miRNAs in progenitor cell-mediated cardiovascular repair. Caution is warranted in interpreting these data since several studies have shown that some common assays used for endothelial progenitors are not resulting in the outgrowth of genuine progenitor cells but angiogenic macrophages.

Targets in post-myocardial infarction

Gianluigi Condorelli (Milan, IT) discussed miR-1, an abundant cardiac miRNA, and its role in IGF-1 signalling. He also pointed out that messenger RNAs themselves may bind miRNAs and regulate their decay.

Developments of anti-miRs and miRmimics as novel therapeutics

Eva Van Rooij (Boulder, US) stated that their company (MiRagene Therapeutics) is currently working on the development of anti-miRs but not miRmimics as novel therapeutics. MiRmimics would result in an upregulation of the miRNA in all cell types. Anti-miRs have at least some degree of specificity by only targeting cells, which express this miRNA, i.e. miR-208 in cardiomyocytes, a regulator of cardiac hypertrophy. First results from a phase II clinical trial on hepatic miR-122 are expected for later this year, which will be important for the entire field.




MicroRNAs - a novel target in cardiovascular prevention

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.